CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
11.41
-0.30 (-2.56%)
Jul 11, 2025, 1:50 PM - Market open
CorMedix Revenue
CorMedix had revenue of $39.08M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $82.55M. In the year 2024, CorMedix had annual revenue of $43.47M.
Revenue (ttm)
$82.55M
Revenue Growth
n/a
P/S Ratio
8.63
Revenue / Employee
$1,270,059
Employees
65
Market Cap
849.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.47M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CRMD News
- 10 days ago - CorMedix Analyst Says Investors Could Be Further Rewarded - Benzinga
- 10 days ago - CorMedix Seems Significantly Undervalued - Seeking Alpha
- 14 days ago - Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 14 days ago - CorMedix Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 14 days ago - CorMedix Inc. Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 18 days ago - CorMedix inc. Announces Customer Implementation - GlobeNewsWire
- 5 weeks ago - CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position - Seeking Alpha
- 5 weeks ago - CorMedix: Exceeding Expectations - Seeking Alpha